Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Medical Genetics · Glycogen Storage Disease Type III

Diagnosing GSD III and Understanding Your Results

At a Glance

Glycogen Storage Disease Type III (GSD III) is definitively diagnosed through genetic testing of the AGL gene, replacing the need for invasive tissue biopsies. Key biochemical clues include low blood sugar with normal lactate levels and elevated Creatine Kinase (CK), which help differentiate it from other forms of GSD.

Getting a clear diagnosis for Glycogen Storage Disease Type III (GSD III) is a multi-step process that has changed significantly in recent years. While doctors used to rely on invasive tissue biopsies, the current gold standard is non-invasive genetic testing [1][2]. This transition means that a definitive answer can now be found through a simple blood or saliva sample, providing a “genetic blueprint” of the condition [2][3].

The Modern Diagnostic Pathway

The journey to a diagnosis usually begins when a doctor notices signs like an enlarged liver (hepatomegaly), low blood sugar (hypoglycemia), or elevated liver enzymes [4][5]. While typically diagnosed in childhood due to an enlarged liver or growth issues, some patients with milder liver symptoms are not diagnosed until adulthood when progressive muscle weakness begins to set in [6][5].

  1. Biochemical Screening: Doctors first look at blood markers. A key clue for GSD III is having low blood sugar combined with normal lactate levels and elevated Creatine Kinase (CK) [7][5].
  2. Genetic Testing (AGL Gene): This is the definitive step. By sequencing the AGL gene, laboratories look for specific errors (mutations) that prevent the body from making the glycogen debranching enzyme [2][1].
  3. Ruling Out Look-Alikes: Because several types of GSD share similar symptoms, doctors must carefully differentiate GSD III from other types [8].

GSD III vs. Look-Alike Conditions

It is common for GSD III to be initially confused with other forms of liver-related glycogen storage disease.

  • GSD I (von Gierke disease): Unlike GSD III, people with GSD I typically have very high levels of lactate (lactic acidosis) and uric acid in their blood [7][9]. They also do not have the muscle or heart involvement seen in GSD IIIa [6][8].
  • GSD VI and IX: These types primarily affect the liver and are often considered “milder” than GSD III. A major difference is that GSD VI and IX do not cause the muscle weakness or elevated CK levels that are hallmarks of GSD IIIa [10][5].

Decoding Your Genetic Report

A complete genetic report is a powerful tool for your medical team. You should ensure your report includes these specific data points to guide your care:

Data Point What It Means Why It Matters
Gene Name Should be AGL [1]. Confirms you are looking at the right condition.
Variant Nomenclature The specific “address” of the mutation (e.g., c.123G>A) [11]. Helps identify the exact type of error in the gene code.
Zygosity Homozygous (two identical mutations) or Compound Heterozygous (two different mutations) [2]. Confirms that both copies of the gene are affected.
Exon Location Which part of the gene is affected (e.g., Exon 3) [12]. Mutations in Exon 3 are often a sign of GSD IIIb, which usually spares the muscles [13].
Classification Labeled as Pathogenic or Likely Pathogenic [3]. Confirms the lab is certain these mutations cause the disease.

If your report contains a Variant of Uncertain Significance (VUS), it means the lab found a change but isn’t yet sure if it causes the disease. In these cases, your doctor may recommend testing parents to see if the change was inherited in a way that fits GSD III [2][14]. Always keep a permanent digital and physical copy of this report, as it is the most important document in your (or your child’s) medical history [11].

Common questions in this guide

How is Glycogen Storage Disease Type III diagnosed?
GSD III is primarily diagnosed through non-invasive genetic testing using a blood or saliva sample. Doctors sequence the AGL gene to look for specific mutations that prevent your body from making the glycogen debranching enzyme.
Why is my Creatine Kinase (CK) level elevated with GSD III?
An elevated Creatine Kinase (CK) level indicates muscle involvement, which is a hallmark of GSD IIIa. This helps doctors differentiate it from other liver-related glycogen storage diseases that usually do not affect the muscles.
What is the difference between GSD I and GSD III?
While both cause low blood sugar, people with GSD I usually have very high lactate and uric acid levels, whereas lactate levels remain normal in GSD III. Additionally, GSD I does not cause the muscle weakness often seen in GSD IIIa.
What does it mean if my genetic report shows a mutation in Exon 3?
Mutations located in Exon 3 of the AGL gene are often a sign of GSD IIIb. This specific subtype primarily affects the liver and usually spares the muscles from weakness.
What should I do if my genetic test shows a Variant of Uncertain Significance (VUS)?
A VUS means the laboratory found a change in your DNA but isn't completely sure if it causes GSD III. Your doctor will likely recommend testing your parents to see how the genetic change was inherited in order to clarify the results.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my (or my child's) genetic report confirm 'homozygous' or 'compound heterozygous' status?
  2. 2.Can you confirm that my lactate levels were normal during my low blood sugar episodes? (To help rule out GSD I).
  3. 3.Are my Creatine Kinase (CK) levels elevated, and what does that tell us about muscle involvement?
  4. 4.Is there any 'variant of uncertain significance' (VUS) on my report that we need to monitor or re-evaluate later?
  5. 5.Given my specific genetic results, are there other family members who should be tested for carrier status?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Late presentation of glycogen storage disease types Ia and III in children with short stature and hepatomegaly.

    Quackenbush D, Devito J, Garibaldi L, Buryk M

    Journal of pediatric endocrinology & metabolism : JPEM 2018; (31(4)):473-478 doi:10.1515/jpem-2017-0209.

    PMID: 29374762
  2. 2

    The biallelic novel pathogenic variants in AGL gene in a chinese patient with glycogen storage disease type III.

    Wang J, Yu Y, Cai C, et al.

    BMC pediatrics 2022; (22(1)):284 doi:10.1186/s12887-022-03252-y.

    PMID: 35578201
  3. 3

    [Analysis of two cases of glycogen storage disease type III due to compound heterozygous variants of AGL gene].

    Zhang M, Wang C, Xie Z, et al.

    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2021; (38(11)):1073-1076 doi:10.3760/cma.j.cn511374-20200803-00578.

    PMID: 34729746
  4. 4

    Glycogen Storage Disease in Twins: When Two Lives Reflect One Silent Battle.

    Shah RK, Khan SA, Devkota D, et al.

    Clinical case reports 2026; (14(1)):e71889 doi:10.1002/ccr3.71889.

    PMID: 41567525
  5. 5

    Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring.

    Halaby CA, Young SP, Austin S, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(12)):2686-2694 doi:10.1038/s41436-019-0561-7.

    PMID: 31263214
  6. 6

    Muscle Ultrasound in Patients with Glycogen Storage Disease Types I and III.

    Verbeek RJ, Sentner CP, Smit GP, et al.

    Ultrasound in medicine & biology 2016; (42(1)):133-42.

    PMID: 26437929
  7. 7

    Beneficial Effects of Modified Atkins Diet in Glycogen Storage Disease Type IIIa.

    Olgac A, İnci A, Okur İ, et al.

    Annals of nutrition & metabolism 2020; (76(4)):233-241 doi:10.1159/000509335.

    PMID: 32712609
  8. 8

    A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III.

    Hijazi G, Paschall A, Young SP, et al.

    Molecular genetics and metabolism reports 2021; (29()):100821 doi:10.1016/j.ymgmr.2021.100821.

    PMID: 34820282
  9. 9

    Mutational analysis and clinical investigations of medically diagnosed GSD 1a patients from Pakistan.

    Gul B, Firasat S, Shan T, et al.

    PloS one 2023; (18(11)):e0288965 doi:10.1371/journal.pone.0288965.

    PMID: 38033126
  10. 10

    Report of an Iranian child with chronic abdominal pain and constipation diagnosed as glycogen storage disease type IX: a case report.

    Zamanfar D, Hashemi-Soteh SM, Ghazaiean M, Keyhanian E

    Journal of medical case reports 2024; (18(1)):14 doi:10.1186/s13256-023-04295-0.

    PMID: 38212860
  11. 11

    Identification of a novel nonsense mutation in the AGL gene in glycogen storage disease type IIIa: first genetically confirmed case report from Morocco.

    Jakani M, Assiri I, El Foutat S, et al.

    Molecular biology reports 2025; (53(1)):195 doi:10.1007/s11033-025-11345-x.

    PMID: 41389110
  12. 12

    Spectrum of amyloglucosidase mutations in Asian Indian patients with Glycogen storage disease type III.

    Perveen S, Gupta N, Kumar M, et al.

    American journal of medical genetics. Part A 2020; (182(5)):1190-1200 doi:10.1002/ajmg.a.61547.

    PMID: 32222031
  13. 13

    Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome.

    Sentner CP, Hoogeveen IJ, Weinstein DA, et al.

    Journal of inherited metabolic disease 2016; (39(5)):697-704 doi:10.1007/s10545-016-9932-2.

    PMID: 27106217
  14. 14

    Uniparental isodisomy of chromosome 1 results in glycogen storage disease type III with profound growth retardation.

    Ponzi E, Alesi V, Lepri FR, et al.

    Molecular genetics & genomic medicine 2019; (7(5)):e634 doi:10.1002/mgg3.634.

    PMID: 30916492

This page explains GSD III diagnostic processes and genetic testing terminology for educational purposes. Your geneticist or metabolic specialist is the best source for interpreting your specific laboratory results.

Get notified when new evidence is published on Glycogen storage disease due to glycogen debranching enzyme deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.